Elinzanetant Shows Promise in Managing Vasomotor Symptoms for Menopausal and Breast Cancer Patients
Discover how Bayer's elinzanetant offers promising relief for vasomotor symptoms in menopausal and breast cancer patients, with significant trial results showing reduced hot flashes and improved sleep.
Metsera’s MET-097i: A Promising Advancement in Long-Acting Obesity Treatment
Metsera announces promising obesity therapy, improving upon current incretin-based drugs by offering longer-lasting effects and fewer side effects, potentially transforming weight management and heart health strategies.
FDA Announces Guidelines for Implementing Artificial Intelligence in Drug Development
The FDA announces their first official guideline on the implementation of artificial intelligence in the drug development process.
Enhancing Clinical Trial Diversity: Insights on Action Plans and Regulatory Alignment
In a recent interview, Rachael Fones, director of government and public affairs at IQVIA, emphasized the importance of diversity action plans in clinical trials.
TEV’749: Teva’s Controlled-Release Schizophrenia Treatment in Phase 3 Trials
In an effort to further address CNS and mental health conditions, Teva Pharmaceuticals is developing TEV'749, a long-acting formulation of olanzapine.
Bridge Biotherapeutics to Present Key Developments at JPM 2025
Bridge Biotherapeutics, a clinical-stage biotech company focusing on therapeutic areas with high unmet needs, has officially been slated to present at the 43rd annual J.P. Morgan Healthcare Conference.
Ionis Pharmaceuticals Achieves Milestone with FDA Approval of Treatment for Familial Chylomicronemia Syndrome (FCS)
Ionis Pharmaceuticals marks a new commercial era with the FDA approval of Tryngolza, a novel RNA-targeted treatment for familial chylomicronemia syndrome, embarking on its first solo drug launch to address unmet medical needs.
SiteOne Therapeutics Secures $100M to Advance Non-Opioid Pain Drug Research
SiteOne Therapeutics lands $100M in funding to develop non-opioid pain medications. Backed by Novo Holdings, the biotech firm aims to demonstrate the effectiveness of its ion channel-focused treatments amidst a challenging market landscape.
The Transformative Role of AI in Clinical Trials and Drug Development
Discover how AI is revolutionizing clinical trials and drug development, enhancing efficiency, accuracy, and patient care, while facing adoption challenges in the biopharma industry.
FDA Identifies New Safety Concerns for Ocaliva in Treating Rare Liver Disease
The FDA has reported additional safety risks linked to Ocaliva, a drug for primary biliary cholangitis, citing serious liver injuries in patients. This marks another setback for the drug, originally poised as a blockbuster.
Cellenkos’ CK0804 Shows Promise in Phase 1b Myelofibrosis Trial
Cellenkos' CK0804 T-regulatory cell therapy demonstrates safety and efficacy in phase 1b trial for myelofibrosis. Encouraging outcomes include reduced spleen volume, symptom relief, and improved transfusion needs.
GSK and Muna Therapeutics Partner to Target Alzheimer’s Treatment
GSK partners with Muna Therapeutics in a major collaboration to develop Alzheimer's treatments, marking a pivotal step in neurodegenerative disease research.
NIH’s TrialGPT: AI’s Potential in Revolutionizing Clinical Trial Recruitment
The NIH has developed TrialGPT, an AI-powered algorithm designed to match patients to suitable clinical trials more efficiently.
Sanofi Unveils $590M Modular Vaccine and Biologics Plant in Singapore
Sanofi has opened a $590 million modular manufacturing facility in Singapore's Tuas Biomedical Park, designed to swiftly adapt production lines for vaccines and biologics. This innovative plant, operational by 2026, aims to bolster pandemic preparedness and strengthen Singapore's biopharma manufacturing presence.
Breakthrough Injection Offers Hope for Asthma and COPD Attacks
A new injection for asthma and COPD attacks shows promise in reducing the need for further treatment by 30%, potentially revolutionizing patient care and improving global health outcomes.
Merck’s Winrevair Shows Promise in Expanding Cardiovascular Treatment Market
Merck's cardiovascular drug Winrevair demonstrates significant efficacy in treating pulmonary arterial hypertension, potentially expanding its market presence as Keytruda faces patent expiration. Recent ZENITH trial results indicate promising outcomes for patients with severe lung hypertension.
Recognizing Patients and Partners: The Rise of Patient Empowerment
Discover how patient empowerment is transforming clinical research. Learn about evolving regulatory guidelines, technology integration, and community-based approaches that enhance patient involvement and decision-making in trials.
Abbott’s Initiative for Enhancing Diversity in Clinical Trials
Abbott's Diversity in Clinical Trials initiative outlines strategies to enhance inclusivity in clinical research, addressing barriers to participation and fostering partnerships to ensure diverse patient representation.
BeiGene Settles Patent Dispute with MSN to Protect Cancer Drug Until 2037
BeiGene secures Brukinsa's market exclusivity until 2037 through a patent settlement with MSN Pharmaceuticals, resolving litigation and safeguarding its blockbuster cancer drug. The agreement allows MSN to launch a generic version in the U.S. in 2037, barring any accelerations or extensions. Concurrently, BeiGene is rebranding to BeOne Medicines as it expands its global cancer drug offerings.
Bridging Data and Trust in Clinical Trial Recruitment
Patient recruitment in clinical trials faces significant challenges, often failing to meet enrollment timelines despite advancements in data-driven strategies. The most successful recruitment approaches integrate data insights with trust-building efforts, tailored to the specific needs of each trial to enhance efficiency and inclusivity.
AbbVie Loses $40 Billion in Market Value as Schizophrenia Drug Trials Disappoint
AbbVie experiences a $40 billion market value drop after its schizophrenia drug, emraclidine, fails in Phase 2 trials. Discover the implications of this failure and what it means for AbbVie’s future in neuroscience.
Making Real-World Data Research-Ready
With increasing use of real-world data (RWD) throughout the drug development cycle — from initial discovery through to market approval and post-market monitoring — comes increasing scrutiny about the quality of the data. This episode of tHEORetically Speaking features Jeff Brown, PhD and Matvey Palchuk, MD, MS, FAMIA of TriNetX, who discuss the rise of RWD and its role in revolutionizing healthcare research, and how the TriNetX team approaches data quality to ensure research-ready RWD.
Making Real-World Data Research-Ready
This episode of tHEORetically Speaking features Jeffrey Brown, PhD and Matvey Palchuk, MD, MS, FAMIA of TriNetX, who discuss the rise of RWD and its role in revolutionizing healthcare research, and how the TriNetX team approaches data quality to ensure research-ready RWD.
Semaglutide Shows Promise in Reducing Pain and Weight for Knee Osteoarthritis Patients in STEP 9 Trial
The STEP 9 trial showed that weekly semaglutide injections significantly reduced knee osteoarthritis pain and body weight in patients with obesity, with improved physical function.
CEO with Type 1 Diabetes Leads Groundbreaking Clinical Trials for Functional Cure
Explore how Jonathan Rigby, CEO of Sernova and type 1 diabetes patient, is pioneering a potential functional cure through innovative clinical trials, achieving insulin independence for patients and raising awareness about the disease.
